Caicun Zhou

34.7k total citations · 6 hit papers
136 papers, 8.9k citations indexed

About

Caicun Zhou is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Caicun Zhou has authored 136 papers receiving a total of 8.9k indexed citations (citations by other indexed papers that have themselves been cited), including 107 papers in Oncology, 106 papers in Pulmonary and Respiratory Medicine and 34 papers in Molecular Biology. Recurrent topics in Caicun Zhou's work include Lung Cancer Treatments and Mutations (103 papers), Lung Cancer Research Studies (54 papers) and Cancer Immunotherapy and Biomarkers (27 papers). Caicun Zhou is often cited by papers focused on Lung Cancer Treatments and Mutations (103 papers), Lung Cancer Research Studies (54 papers) and Cancer Immunotherapy and Biomarkers (27 papers). Caicun Zhou collaborates with scholars based in China, United States and United Kingdom. Caicun Zhou's co-authors include Yi‐Long Wu, Shengxiang Ren, Shun Lü, Sarayut Lucien Geater, Chengping Hu, James Chih‐Hsin Yang, Tao Jiang, Jifeng Feng, Wěi Li and Jian Hua Shi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Caicun Zhou

132 papers receiving 8.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

2014 1.6k citations Yi‐Long Wu, Caicun Zhou et al. profile →
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

2012 776 citations Vera Hirsh, Keunchil Park et al. profile →
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

2015 715 citations James Chih‐Hsin Yang, Lecia V. Sequist et al. profile →
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

2018 511 citations Byoung Chul Cho, Manuel Cobo et al. Journal of Clinical Oncology profile →
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients

2018 390 citations Zhe Yang, Nong Yang et al. Clinical Cancer Research profile →
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

2019 265 citations Yi‐Long Wu, Shun Lü et al. Journal of Thoracic Oncology profile →

Peers

Countries citing papers authored by Caicun Zhou

Since Specialization

Citations

This map shows the geographic impact of Caicun Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caicun Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caicun Zhou more than expected).

Fields of papers citing papers by Caicun Zhou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caicun Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caicun Zhou. The network helps show where Caicun Zhou may publish in the future.

Co-authorship network of co-authors of Caicun Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Caicun Zhou. A scholar is included among the top collaborators of Caicun Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caicun Zhou. Caicun Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PP01.24 FURVENT: Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004) 2024 ·Journal of Thoracic Oncology ·Alexander I. Spira, Byoung Chul Cho, Enriqueta Felip, Edward B. Garon, Kōichi Goto, Melissa Johnson, Natasha B. Leighl, Antonio Passaro, David Planchard, Sanjay Popat, James Chih‐Hsin Yang, Xiaoqian Lu, Yong Jiang, (unknown), (unknown), Marcin Kowanetz, Shirley Wang, John T. Le, Jerry Y. Hsu, Caicun Zhou	0
2	Results of a phase 1/2 study of MHB088C: A novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors. 2024 ·Journal of Clinical Oncology ·Lin Shen, Caicun Zhou, (unknown), (unknown), Yinghua Ji, Haihua Yang, (unknown), Liang Han, (unknown), Meili Sun, Qing Wen, Xinmin Yu, Yuming Jia, Hai Huang, (unknown), Zhiye Zhang, (unknown), Zhen Zhang, Junwei Shi, (unknown)	9
3	Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations 2024 ·European Journal of Cancer ·Daniel L. Hertz, Markus Joerger, Yung‐Jue Bang, Ron H.J. Mathijssen, Caicun Zhou, Li Zhang, David R. Gandara, Michael Stahl, Bradley J. Monk, Ulrich Jaehde, Jan H. Beumer	15
4	LBA5 Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study 2023 ·Annals of Oncology ·N. Girard, K. Park, Kun Tang, Byoung Chul Cho, Luis Paz‐Ares, Sunfa Cheng, Satoru Kitazono, (unknown), (unknown), Joshua K. Sabari, Rachel E. Sanborn, Aaron S. Mansfield, J-Y. Hung, Sanjay Popat, Josiane Mourão Dias, (unknown), (unknown), (unknown), Roland E. Knoblauch, Caicun Zhou	5
5	EP08.02-33 Induction Immunochemotherapy Before Definitive Chemoradiotherapy for Unresectable Locally Advanced Non-small Cell Lung Cancer 2023 ·Journal of Thoracic Oncology ·Liang Wu, (unknown), Caicun Zhou, (unknown)	1
6	Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma 2021 ·OncoTargets and Therapy ·Hao Wang, Shanhao Chen, (unknown), Chunyan Wu, Junjie Zhu, Minlin Jiang, Jing Ning, Shengyu Wu, Lijia Wu, Jingjie Li, Bin Chen, Sha Zhao, Wěi Li, Jia Yu, Qiyu Fang, (unknown), Wencheng Zhao, Yayi He, Caicun Zhou	9
7	A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer 2020 ·Investigational New Drugs ·Jin‐Ji Yang, Jian Fang, Yongqian Shu, Jianhua Chang, Gongyan Chen, (unknown), Wěi Li, Xiaoqing Liu, Nong Yang, Caicun Zhou, Jian Huang, Melanie M. Frigault, Ryan J. Hartmaier, (unknown), Coumaran Égile, Shethah Morgan, Remy B. Verheijen, Anders Mellemgaard, Liu Yang, Yi‐Long Wu	43
8	Tumor neoantigens: from basic research to clinical applications 2019 ·Journal of Hematology & Oncology ·Tao Jiang, Tao Shi, Henghui Zhang, Jie Hu, Yuanlin Song, Jia Wei, Shengxiang Ren, Caicun Zhou	277
9	Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer 2019 ·Lung Cancer ·Sha Zhao, Guanghui Gao, Wei Li, Xuefei Li, Chao Zhao, Tao Jiang, Yijun Jia, Yayi He, Aiwu Li, Chunxia Su, Shengxiang Ren, Xiaoxia Chen, Caicun Zhou	121
10	Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients breakdown → 2018 ·Clinical Cancer Research ·Zhe Yang, Nong Yang, Qiuxiang Ou, Yi Xiang, Tao Jiang, Xue Wu, Hua Bao, Xiaoling Tong, Xiaonan Wang, Yang Shao, Yunpeng Liu, Yan Wang, Caicun Zhou	390
11	Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer 2018 ·Lung Cancer ·Yijun Jia, Xuefei Li, Chao Zhao, Tao Jiang, Sha Zhao, Limin Zhang, Xiaozhen Liu, Jinpeng Shi, Meng Qiao, (unknown), (unknown), Ruoshuang Han, Xiaoxia Chen, Caicun Zhou	12
12	Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies 2018 ·Lung Cancer ·Yi‐Long Wu, Victor Lee, Chong Kin Liam, Shun Lü, Keunchil Park, Vichien Srimuninnimit, Jie Wang, Caicun Zhou, (unknown), Peter Button, Gregory Hooper, John F. Palma, Katja Schulze, Sidney Scudder, David S. Shames, (unknown), Guili Zhang, Tony Mok	35
13	The heterogeneity of PD-L1 expression among the different histological components and metastatic lymph nodes in patients with resected lung adenosquamous carcinoma 2017 ·Annals of Oncology ·Yanbiao Liu, Shengxiang Ren, Yingying Peng, Chunyan Wu, (unknown), Fengying Wu, (unknown), Yue Pan, Caicun Zhou	8
14	138PD: Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6) 2016 ·Journal of Thoracic Oncology ·Martin Schüler, James Chih‐Hsin Yang, Lecia V. Sequist, Nobuyuki Yamamoto, Caicun Zhou, Kenneth J. O’Byrne, Vera Hirsh, Tony Mok, Riyaz Shah, Yi‐Long Wu	2
15	443P Phase III trial of afatinib vs erlotinib in patients (pts) with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes 2015 ·Annals of Oncology ·(unknown), W. Li, Caicun Zhou, Enriqueta Felip, Manuel Cobo, Glenwood Goss, Jean‐Charles Soria, (unknown), Nicole Krämer, Vikram K. Chand, Flavio Solca, Shun Lü	1
16	Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer 2015 ·Journal of Thoracic Oncology ·Sarayut Lucien Geater, Chong‐Rui Xu, Caicun Zhou, Chengping Hu, Jifeng Feng, Shun Lü, Yunchao Huang, Wěi Li, Mei Hou, Jian Hua Shi, Kye Young Lee, Michael Palmer, Yang Shi, Juliane Lungershausen, Yi‐Long Wu	49
17	Atypical Negative ALK Break-Apart FISH Harboring a Crizotinib-Responsive ALK Rearrangement in Non–Small-Cell Lung Cancer 2014 ·Journal of Thoracic Oncology ·Shengxiang Ren, Fred R. Hirsch, Marileila Varella‐Garcia, Dara L. Aisner, Theresa A. Boyle, Caicun Zhou, D. Ross Camidge	50
18	EBUS-TBNA Provides Highest RNA Yield for Multiple Biomarker Testing from Routinely Obtained Small Biopsies in Non-Small Cell Lung Cancer Patients - A Comparative Study of Three Different Minimal Invasive Sampling Methods 2013 ·PLoS ONE ·Gerald Schmid‐Bindert, Yongsheng Wang, (unknown), Hui Sun, Thomas Henzler, Hao Wang, Lothar R. Pilz, Shengxiang Ren, Caicun Zhou	38
19	ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer 2010 ·Medical Oncology ·Chunxia Su, Songwen Zhou, Ling Zhang, Shengxiang Ren, Jianfang Xu, Jie Zhang, (unknown), Caicun Zhou	60
20	Curative effect of gemcitabine combined with platinum drugs on treatment of advanced squamous carcinoma and adenocarcinoma of lung 2009 ·Journal of Tongji University ·Caicun Zhou	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact